The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
The trial will be conducted across eight sites in Maharashtra
The company has to approach the DCGI for approval to commence the trials
The module offers the first preclinical laboratory information system of its kind that is fully integrated into the digital pathology workflow and provides efficient pathological studies of whole slides
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Subscribe To Our Newsletter & Stay Updated
